Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation

Low-grade serous ovarian cancer (LGSOC) is now considered a different entity from high-grade serous ovarian cancer. The chemoresistance inherent to this type of ovarian cancer narrows the therapeutic options, especially in the recurrent setting. It is thought that the mitogen-activated protein kinas...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bárbara Lima, Miguel Henriques Abreu, Susana Sousa, Carla Bartosch, Deolinda Pereira
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2022-04-01
Col·lecció:	Gynecologic Oncology Reports
Matèries:	Low-grade serous ovarian cancer BRAF mutation Dabrafenib Trametinib Combination treatment
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2352578922000224
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!